New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
11:03 EDTGE, SSYS, JNJ, XONE, DDD, SYK, VJET3D printer makers tumble after profit warning from 3D Systems
Shares of 3D printer makers are sinking after the largest company in the sector in terms of market capitalization, 3D Systems (DDD), pre-announced lower than expected fiscal 2013 profit and gave a disappointing earning outlook for next year. WHAT'S NEW: 3D Systems reduced its fiscal 2013 earnings per share outlook to 83c-87c from 93c-$1.03. Analysts' consensus estimate was 96c. However, the company reported preliminary fiscal 2013 revenue of $513 million-$514 million, within its previous outlook of $500M-$530M. Analysts' consensus estimate was $514.24M. 3D Systems blamed its lower than expected fiscal 2013 EPS on "very significant R&D, manufacturing and marketing investments designed to accelerate revenue growth," along with weaker than expected demand for its parts and consumer products. For fiscal 2014, 3D Systems predicted that its EPS would be 73c-85c, versus analysts' consensus estimate of $1.27. However, the 3D printer maker expects its fiscal 2014 revenue to come in at $680M-$720M, versus the consensus estimate of $671.29M. ANALYST REACTION: In a note to investors earlier today, Jefferies analyst Peter Misek wrote that 3D Systems' opportunity in the professional and industrial markets is "only just beginning." 3D Systems' guidance is "appropriately conservative," wrote Misek, adding that his research suggests that the 3D printer maker is likely to announce deals with at least three major companies in 2014: Stryker (SYK), Johnson & Johnson (JNJ), and GE (GE). Misek kept a Buy rating on the stock. PRICE ACTION: In mid-morning trading, 3D Systems tumbled 22% to $59.25, but the stock was well above its low for the day of $54.63. Likewise, another major 3D printer maker, Stratasys (SSYS), retreated 8% to $108.60, but was well off its low for the day of $102.20. Another company in the space, ExOne (XONE), sank 10% to $40.27, while European 3D printer maker Voxeljet (VJET) gave back 6% to trade near $32.
News For DDD;SSYS;VJET;XONE;GE;SYK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 15, 2014
12:01 EDTGEBioTime unit, GE Healthcare sign set of license agreements, terms not disclosed
BioTime (BTX) announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare (GE) have signed a set of license agreements through which GEHC received rights to ESIís stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
11:17 EDTGEGE Aviation selected by Boeing for 777x common core avionics systems
Subscribe for More Information
10:44 EDTVJET, XONE, SSYS, DDD3D Systems CEO says 3D printing to transition to production in '15, says UBS
UBS quotes 3D Systems (DDD) CEO Avi Reichental as saying that 3D printing will transition to producing from prototyping in 2015. He believes that 3D Systems' investments should begin to pay off in 2015, and make it the best company in the space. UBS keeps a Neutral rating on the shares but says that a short squeeze in the stock could occur if the company begins to report positive results. Other names in the space include Stratasys (SSYS), Voxeljet (VJET), and ExOne (XONE).
08:15 EDTGEGeneral Electric to host investor meeting
Subscribe for More Information
08:08 EDTGEGeneral Electric enters into IP licensing agreement with WordLogic
Subscribe for More Information
December 12, 2014
14:01 EDTJNJGenOn Energy to receive $3M milestone payment in Janssen collaboration
Genmab announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech (JNJ), triggering a $3M payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Today's news will not impact Genmab's 2014 financial guidance.
11:57 EDTGEGeneral Electric increases dividend 5% to 23c from 22c
Subscribe for More Information
11:57 EDTGEGeneral Electric increases dividend 5% to 23c from 22c
Subscribe for More Information
December 10, 2014
10:00 EDTSSYS, DDDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with an Underperform at Longbow... AutoZone (AZO) initiated with a Buy at Nomura... C.H. Robinson (CHRW) initiated with a Neutral at Nomura... CSX (CSX) initiated with a Buy at Nomura... CVS Health (CVS) initiated with a Neutral at Citigroup... Canadian National (CNI) initiated with a Neutral at Nomura... Carrizo Oil & Gas (CRZO) initiated with a Buy at Canaccord... CenterPoint Energy (CNP) initiated with a Neutral at Nomura... Con-way (CNW) initiated with a Neutral at Nomura... Cornerstone OnDemand (CSOD) initiated with a Buy at BofA/Merrill... Depomed (DEPO) initiated with an Outperform at RBC Capital... Dollar General (DG) initiated with a Buy at Citigroup... Dollar Tree (DLTR) initiated with a Neutral at Citigroup... Dynagas LNG (DLNG) initiated with a Buy at ABN Amro... EMC (EMC) initiated with a Neutral at JPMorgan... Energy Focus (EFOI) initiated with a Buy at Roth Capital... Expeditors (EXPD) initiated with a Neutral at Nomura... GasLog (GLOG) initiated with a Buy at ABN Amro... Genesee & Wyoming (GWR) initiated with a Neutral at Nomura... Golar LNG (GLNG) initiated with a Sell at ABN Amro... HII Technologies (HIIT) initiated with a Buy at Roth Capital... Hudbay Minerals (HBM) initiated with an Overweight at Barclays... J.B. Hunt (JBHT) initiated with a Buy at Nomura... Kansas City Southern (KSU) initiated with a Buy at Nomura... Kroger (KR) initiated with a Buy at Citigroup... Lear (LEA) initiated with a Buy at Northcoast... Lundin Mining (LUNMF) initiated with an Overweight at Barclays... NetApp (NTAP) initiated with a Neutral at JPMorgan... Norfolk Southern (NSC) initiated with a Neutral at Nomura... PROS (PRO) initiated with an Outperform at Pacific Crest... Qlik Technologies (QLIK)initiated with a Buy at BofA/Merrill... Rentokil (RTOKY) initiated with a Neutral at UBS... Revolution Lighting (RVLT) initiated with a Buy at Roth Capital... ServiceNow (NOW) initiated with a Buy at BofA/Merrill... Stratasys (SSYS) initiated with a Neutral at Longbow... Suburban Propane (SPH) initiated with a Hold at Stifel... Tableau (DATA) initiated with a Buy at BofA/Merrill... Teekay LNG (TGP) initiated with a Buy at ABN Amro... Tessera (TSRA) initiated with a Buy at Sidoti... Union Pacific (UNP) initiated with a Buy at Nomura... Viper Energy (VNOM) initiated with a Buy at Stifel... Visteon (VC) initiated with a Buy at Northcoast... Walgreen (WAG) initiated with a Buy at Citigroup... Werner (WERN) initiated with a Neutral at Nomura.
08:04 EDTGEGE Energy Financial Services, Pacifico to build second joint solar project
Subscribe for More Information
07:54 EDTSSYS, DDDPullback in 3D printers creates buying opportunity, says Stifel
Subscribe for More Information
06:48 EDTDDD3D Systems initiated with an Underperform at Longbow
Target $25.
06:33 EDTSSYSStratasys initiated with a Neutral at Longbow
Subscribe for More Information
December 9, 2014
12:35 EDTSSYSStratasys management to meet with Jefferies
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
12:42 EDTSYKStryker resolves government investigation of OtisMed matter
Subscribe for More Information
07:54 EDTSSYSStratasys weakness creates attractive entry point, says UBS
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use